Serum S100ß Levels Are Linked with Cognitive Decline and Peripheral Inflammation in Spinocerebellar Ataxia Type 2.

Experimental and clinical studies have indicated a potential role of the protein S100ß in the pathogenesis and phenotype of neurodegenerative diseases. However, its impact on spinocerebellar ataxia type 2 (SCA2) remains to be elucidated. The objective of the study is to determine the serum levels of S100ß in SCA2 and its relationship with molecular, clinical, cognitive, and peripheral inflammatory markers of the disease. Serum concentrations of S100ß were measured by enzyme-linked immunosorbent assay in 39 SCA2 subjects and 36 age- and gender-matched controls. Clinical scores of ataxia, non-ataxia symptoms, cognitive dysfunction, and some blood cell count-derived inflammatory indices were assessed. The SCA2 individuals manifested S100ß levels similar to the control group, at low nanomolar concentrations. However, the S100ß levels were directly associated with a better performance of cognitive evaluation within the SCA2 cohort. Moreover, the S100ß levels were inversely correlated with most peripheral inflammatory indices. Indeed, the neutrophil-to-lymphocyte ratio significantly mediated the effect of serum S100ß on cognitive performance, even after controlling for the ataxia severity in the causal mediation analysis. Our findings suggested that, within physiologic concentrations, the protein S100ß exerts a neuroprotective role against cognitive dysfunction in SCA2, likely via the suppression of pro-inflammatory mechanisms.

Peripheral Inflammation Links with the Severity of Clinical Phenotype in Spinocerebellar Ataxia 2.

BACKGROUND: The role of peripheral inflammation in spinocerebellar ataxia type 2 (SCA2) is unknown. OBJECTIVE: The objective of this study was to identify peripheral inflammation biomarkers and their relationship with the clinical and molecular features. METHODS: Blood cell count-derived inflammatory indices were measured in 39 SCA2 subjects and their matched controls. Clinical scores of ataxia, nonataxia, and cognitive dysfunction were assessed. RESULTS: The neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the Systemic Inflammation Index (SII), and the Aggregate Index of Systemic Inflammation (AISI) were significantly increased in SCA2 subjects compared with controls. The increases in PLR, SII, and AISI were even observed in preclinical carriers. NLR, PLR, and SII were correlated with the Scale for the Assessment and Rating of Ataxia speech item score rather than with the total score. The NLR and SII were correlated with the nonataxia and the cognitive scores. CONCLUSIONS: Peripheral inflammatory indices are biomarkers in SCA2, which may help to design future immunomodulatory trials and advance our understanding of the disease. © 2023 International Parkinson and Movement Disorder Society.

A Possible Case of Centronuclear Myopathy: A Case Report.

Congenital myopathies (CMs) are a group of diseases that primarily affect the muscle fiber, especially the contractile apparatus and the different components that condition its normal functioning. They present as muscle weakness and hypotonia at birth or during the first year of life. Centronuclear CM is characterized by a high incidence of nuclei located centrally and internally in muscle fibers. Clinical case: a 22-year-old male patient with symptoms of muscle weakness since early childhood, with difficulty in performing physical activity according to his age, with the presence of a long face, a waddling gait, and a global decrease in muscle mass. Electromyography was performed, showing a neurogenic pattern and not the expected myopathic one, neuroconduction with reduced amplitude of the motor potential of the peroneal nerve and axonal and myelin damage of the posterior tibial nerves. The microscopic study of the studied striated muscle fragments stained with hematoxylin-eosin and Masson's trichrome showed the presence of fibers with central nuclei, diagnosing CM. The patient meets most of the description for CM, with involvement of all striated muscles, although it is important to note the neurogenic pattern present in this case, due to the denervation of damaged muscle fibers, which contain terminal axonal segments. Neuroconduction shows the involvement of motor nerves, but with normal sensory studies, axonal polyneuropathy is unlikely, due to normal sensory potentials. Different pathological findings have been described depending on the mutated gene in this disease, but all coincide with the presence of fibers with central nuclei for diagnosis by this means, which is so important in institutions where it is not possible to carry out genetic studies, and allowing early specific treatment, according to the stage through which the patient passes.

Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It?

Autism spectrum disorder (ASD) is a group of complex multifactorial neurodevelopmental disorders characterized by a wide and variable set of neuropsychiatric symptoms, including deficits in social communication, narrow and restricted interests, and repetitive behavior. The immune hypothesis is considered to be a major factor contributing to autism pathogenesis, as well as a way to explain the differences of the clinical phenotypes and comorbidities influencing disease course and severity. Evidence highlights a link between immune dysfunction and behavioral traits in autism from several types of evidence found in both cerebrospinal fluid and peripheral blood and their utility to identify autistic subgroups with specific immunophenotypes; underlying behavioral symptoms are also shown. This review summarizes current insights into immune dysfunction in ASD, with particular reference to the impact of immunological factors related to the maternal influence of autism development; comorbidities influencing autism disease course and severity; and others factors with particular relevance, including obesity. Finally, we described main elements of similarities between immunopathology overlapping neurodevelopmental and neurodegenerative disorders, taking as examples autism and Parkinson Disease, respectively.

Effect of non-invasive brain stimulation on behavior and serum brain-derived neurotrophic factor and insulin-like growth factor-1 levels in autistic patients.

Aberrant neural connectivity and intra-cortical inhibitory dysfunction are key features of autism. Non-invasive brain stimulation (NIBS) protocols have been proposed that modulate this aberrant plasticity. However, additional investigations are needed to evaluate the impact of this intervention on biological biomarkers of the disease. We recently demonstrated alterations in serum insulin-like growth factor-1 (IGF-1) and brain-derived neurotrophic factor (BDNF) immunoreactivity in subjects with autism compared to controls. The aim of this pilot study was to explore the change in serum levels of the neurotrophic factors BDNF and IGF-1 in patients undergoing NIBS therapy. Sixteen subjects with autism spectrum disorder (ASD) were tested 1 week before and 1 week after NIBS to determine the short-term outcome on behavior using the total score on the autism behavior checklist, autism treatment evaluation checklist, clinical global impression severity and the autism diagnostic interview. ASD subjects younger than 11 years old (n = 11) were treated with transcranial direct current stimulation (tDCS), and those 11 years and older (n = 5) were treated with repetitive transcranial magnetic stimulation (rTMS). Serum levels of BDNF and IGF-1 were evaluated by Enzyme-Linked Immuno-Sorbent Assay before and after the intervention with NIBS. A significant reduction in scores on the clinical behavioral scales was observed in patients treated with NIBS (ABC-T p = .002, CGI-S p = .008, ADI-T and ATEC-T p < .0001). There was a trend towards reduced serum BDNF levels after NIBS (p = .061), while there was no change in IGF-1 levels. These data support further studies on the potential of BDNF as a biomarker to measure the effectiveness of NIBS in autism.

Cell Immortalization: In Vivo Molecular Bases and In Vitro Techniques for Obtention.

Somatic human cells can divide a finite number of times, a phenomenon known as the Hayflick limit. It is based on the progressive erosion of the telomeric ends each time the cell completes a replicative cycle. Given this problem, researchers need cell lines that do not enter the senescence phase after a certain number of divisions. In this way, more lasting studies can be carried out over time and avoid the tedious work involved in performing cell passes to fresh media. However, some cells have a high replicative potential, such as embryonic stem cells and cancer cells. To accomplish this, these cells express the enzyme telomerase or activate the mechanisms of alternative telomere elongation, which favors the maintenance of the length of their stable telomeres. Researchers have been able to develop cell immortalization technology by studying the cellular and molecular bases of both mechanisms and the genes involved in the control of the cell cycle. Through it, cells with infinite replicative capacity are obtained. To obtain them, viral oncogenes/oncoproteins, myc genes, ectopic expression of telomerase, and the manipulation of genes that regulate the cell cycle, such as p53 and Rb, have been used.

COVID-19 and the Nervous System from a Cuban Experience.

Neuropsychiatric manifestations of viral infections (both per se and secondary to the neuroinflammatory reaction of the host) are mainly attributed to immunological reactions, so many aspects of their pathogenesis are still nuclear. Some novel therapeutic strategies are progressively emerging in which a vaccination may be having a particular impact on recovery and reduction of death. In this context, it is accepted that the SARS-CoV-2 virus is profoundly neurotropic and neuroinvasive, with various effects on the nervous system, although there is no complete understanding of the mechanism of neuroinvasion, brain injury, or short- or long-term neuropsychiatric sequelae. Therefore, it is necessary to understand the post-infectious manifestations of COVID-19 to guide the management of neuropsychiatric diseases. Thus, based on different research groups focused on this field, in this manuscript we summarize papers on COVID-19 and the nervous system (NS) published in a series of articles by Cuban authors. This review focuses on cognitive and affective emotional states, pathogenesis, biomarkers, clinical manifestations, and intervention strategies.

BDNF, proBDNF and IGF-1 serum levels in naïve and medicated subjects with autism.

Brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1) promote the development and maintenance of neural circuits. Alterations in these factors might contribute to autism spectrum disorder (ASD). We asked whether serum BDNF, proBDNF, and IGF-1 levels are altered in an ASD population compared to controls. We measured serum BDNF, proBDNF, and IGF-1 immunoreactive protein in boys and girls aged 5-15 years old with mild to moderate ASD and non-autistic controls by ELISA. IGF-1 was increased in ASD serum compared to controls and was correlated with age and with CARS scores. Serum BDNF levels did not differ between groups, however, proBDNF serum levels were decreased in subjects with ASD compared to non-autistic controls. Medicated, but not unmedicated, ASD subjects exhibited lower serum proBDNF levels compared to controls, while neither IGF-1 nor BDNF levels differed between treatment groups. These data support the involvement of proBDNF and IGF-1 in the pathogenesis and treatment of autism.

Impact of SARS-CoV-2 on neuropsychiatric disorders.

Evolving data show a variable expression of clinical neurological manifestations in patients suffering with coronavirus disease 2019 (COVID-19) from early disease onset. The most frequent symptoms and signs are fatigue, dizziness, impaired consciousness, ageusia, anosmia, radicular pain, and headache, as well as others. Based on the high number of series of cases reported, there is evidence for the implication of the immune system in the pathological mechanism of COVID-19. Although the exact role of the immunological mechanism is not elucidated, two main mechanisms are suggested which implicate the direct effect of severe acute respiratory syndrome coronavirus 2 infection in the central nervous system and neuroinflammation. In the context of neurological manifestations associated with COVID-19, neuropsychiatric disorders show an exacerbation and are described by symptoms and signs such as depression, anxiety, mood alterations, psychosis, post-traumatic stress disorder, delirium, and cognitive impairment, which appear to be common in COVID-19 survivors. A worsened score on psychopathological measures is seen in those with a history of psychiatric comorbidities. We review the neuropsychiatric manifestations associated with COVID-19 and some critical aspects of the innate and adaptive immune system involved in mental health disorders occurring in COVID-19.

Neuroinflammation and Neuromodulation in Neurological Diseases.

Neuroimmunology is a relatively young science. This discipline has emerged today from the research field as a mature and fully developed innovative research area that integrates not only pure topics of neuroimmunology, but also expands on wider fields such as neuroplasticity, neuronal reserve and neuromodulation in association with clinical events, amongst which behavioral disorders stand out. The Cuban School of Neuroimmunology-a recent meeting that took place in Havana, Cuba-focused on topics based on the molecular mechanisms of neuroinflammation in neurological disorders involving behavioral manifestations, such as multiple sclerosis (MS), autism, cerebellar ataxias, Alzheimer´s disease and stroke among others, as well as on the use of new interventional technologies in neurology. Professor Luis Velazquez, from the Cuban Academy of Sciences, dictated an interesting lecture on Spinocerebellar ataxias, a genetic disorder where recent hypotheses related to the influence of neuroinflammation as a neurobiological factor influencing the progression of this disease have emerged. At the same time, the use of new interventional technologies in neurology was discussed, including those referring to novel disease modifying therapies in the course of MS and the use of transcranial magnetic stimulation in several neurological diseases, the latter reinforcing how interventional strategies in the form of non-invasive bran stimulation can contribute to physical rehabilitation in neurology. This paper summarizes the highlights of the most relevant topics presented during the First Cuban School of Neuroimmunology, organized by the Cuban Network of Neuroimmunology, held in June 2019.

Neuroimmunology Research. A Report from the Cuban Network of Neuroimmunology.

Neuroimmunology can be traced back to the XIX century through the descriptions of some of the disease’s models (e.g., multiple sclerosis and Guillain Barret syndrome, amongst others). The diagnostic tools are based in the cerebrospinal fluid (CSF) analysis developed by Quincke or in the development of neuroimmunotherapy with the earlier expression in Pasteur’s vaccine for rabies. Nevertheless, this field, which began to become delineated as an independent research area in the 1940s, has evolved as an innovative and integrative field at the shared edges of neurosciences, immunology, and related clinical and research areas, which are currently becoming a major concern for neuroscience and indeed for all of the scientific community linked to it. The workshop focused on several topics: (1) the molecular mechanisms of immunoregulation in health and neurological diseases, (like multiple sclerosis, autism, ataxias, epilepsy, Alzheimer and Parkinson’s disease); (2) the use of animal models for neurodegenerative diseases (ataxia, fronto-temporal dementia/amyotrophic lateral sclerosis, ataxia-telangiectasia); (3) the results of new interventional technologies in neurology, with a special interest in the implementation of surgical techniques and the management of drug-resistant temporal lobe epilepsy; (4) the use of non-invasive brain stimulation in neurodevelopmental disorders; as well as (5) the efficacy of neuroprotective molecules in neurodegenerative diseases. This paper summarizes the highlights of the symposium.

Rotating and Neurochemical Activity of Rats Lesioned with Quinolinic Acid and Transplanted with Bone Marrow Mononuclear Cells.

Huntington's disease (HD) is an inherited, neurodegenerative disorder that results from the degeneration of striatal neurons, mainly GABAergic neurons. The study of neurochemical activity has provided reliable markers to explain motor disorders. To treat neurodegenerative diseases, stem cell transplants with bone marrow (BM) have been performed for several decades. In this work we determine the effect of mononuclear bone marrow cell (mBMC) transplantation on the rotational behavior and neurochemical activity in a model of Huntington's disease in rats. Four experimental groups were organized: Group I: Control animals (n = 5); Group II: Lesion with quinolinic acid (QA) in the striatum (n = 5); Group III: Lesion with QA and transplant with mBMC (n = 5); Group IV: Lesion with QA and transplant with culture medium (Dulbecco's modified Eagle's medium (DMEM) injection) (n = 5). The rotational activity induced by D-amphetamine was evaluated and the concentration of the neurotransmitter amino acids (glutamate and GABA) was studied. The striatal cell transplantation decreases the rotations induced by D-amphetamine (p < 0.04, Wilcoxon matched pairs test) and improves the changes produced in the levels of neurotransmitters studied. This work suggests that the loss of GABAergic neurons in the brain of rats lesioned with AQ produces behavioral and neurochemical alterations that can be reversed with the use of bone marrow mononuclear cell transplants.

Peripheral Inflammatory Markers Contributing to Comorbidities in Autism.

This study evaluates the contribution of peripheral biomarkers to comorbidities and clinical findings in autism. Seventeen autistic children and age-matched typically developing (AMTD), between three to nine years old were evaluated. The diagnostic followed the Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DMS-IV) and the Childhood Autism Rating Scale (CARS) was applied to classify the severity. Cytokine profile was evaluated in plasma using a sandwich type ELISA. Paraclinical events included electroencephalography (EEG) record. Statistical analysis was done to explore significant differences in cytokine profile between autism and AMTD groups and respect clinical and paraclinical parameters. Significant differences were found to IL-1ß, IL-6, IL-17, IL-12p40, and IL-12p70 cytokines in individuals with autism compared with AMTD (p < 0.05). All autistic patients showed interictalepileptiform activity at EEG, however, only 37.5% suffered epilepsy. There was not a regional focalization of the abnormalities that were detectable with EEG in autistic patients with history of epilepsy. A higher IL-6 level was observed in patients without history of epilepsy with interictalepileptiform activity in the frontal brain region, p < 0.05. In conclusion, peripheral inflammatory markers might be useful as potential biomarkers to predict comorbidities in autism as well as reinforce and aid informed decision-making related to EEG findings in children with Autism spectrum disorders (ASD).

Comorbilidad en pacientes con trastornos del neurodesarrollo / Comorbility in patients with neurodevelopmental disorders

Introducción: El término trastornos del neurodesarrollo incluye diferentes combinaciones de deficiencias en las habilidades esperadas para la edad cronológica de un niño, considerando las esferas motoras, del lenguaje, la socialización, sensorial y el control de esfínter, y en los pacientes afectados pueden asociarse algunas enfermedades (comorbilidad). Objetivo: Examinar las principales comorbilidades crónicas que pueden presentarse en pacientes con trastornos del neurodesarrollo. Métodos: Las fuentes de búsquedas fueron las bases de datos computarizadas: PubMed, Ebsco, SciELO. Además, referencias identificadas en los artículos revisados y que se consideraron importantes y con validez científica. con diez años o menos de publicación, 42/59 se publicaron en los últimos cinco años. Se utilizaron para la búsqueda las palabras clave: trastornos del neurodesarrollo, desarrollo infantil, comorbilidad, trastorno autístico; en idioma español, inglés, o francés, en dependencia de la fuente Resultados: Las comorbilidades más frecuentes, o importantes por su implicación en la vida de los pacientes con trastornos del neurodesarrollo son: la epilepsia, los trastornos de la audición y la visión, las enfermedades mentales, las dificultades en la deglución y el estado nutricional deficiente. Consideraciones finales: La ocurrencia de comorbilidad en pacientes con trastornos del neurodesarrollo es frecuente, puede presentarse en el sistema nervioso o en otros sistemas del organismo y contribuye a que la calidad de vida de estos pacientes se afecte en mayor cuantía(AU)

Introduction: The term neurodevelopmental disorder includes different combinations of deficiencies in the abilities expected for the chronological age of a child, taking into account the motor, speech, socialization, sensorial and sphincter control's scopes, and in the affected patients can be related some diseases (comorbility). Objective: To examine the main chronic comorbilities that can present in patients with neurodevelopmental disorders. Methods: The search sources were computerized databases as: PubMed, Ebsco, SciELO; also references identified in the reviewed articles and that were considered as important and with scientific validity, with ten or less years of being published. 42 of 59 were published in the last five years. There were used for the search the following keywords in Spanish, English and French languages, depending on the source: neurodevelopmental disorders, children development, comorbility, autistic disorder. Results: The most frequent comorbilities or the ones which are important due to their impact in the life of patients with neurodevelopmental disorders are: epilepsy, audition and sight disorders, mental conditions, deglutition difficulty and poor nutritional state. Final considerations: The occurrence of comorbility in patients with neurodevelopmental disorders is frequent; it can be present in the nervous system or in other systems of the body, and it contributes for the life quality of these patients being less affected(AU)

Niveles de plomo y daño en el ADN en niños con trastornos del espectro autista / Lead levels and DNA damage in children with autistic spectrum disorders

Introducción: los trastornos del espectro autista se consideran una familia de alteraciones del neurodesarrollo, caracterizada por dificultades en la comunicación y la interacción social, así como la existencia de un comportamiento estereotipado y repetitivo. Aunque existen varias hipótesis que involucran a factores genéticos y ambientales en su etiopatogenia, la verdadera contribución de estos aún se desconoce. En este estudio se explora la relación entre los niveles séricos de plomo, el daño del ADN y la severidad del autismo. Métodos: se estudiaron 15 niños con el diagnóstico de trastornos del espectro autista entre 4 y 11 años de edad y un grupo control del mismo rango de edad. El coeficiente de inteligencia fue evaluado mediante la prueba de Terman-Merrill y los niños fueron clasificados en dos grados de retardo mental (ligero y moderado/severo). Los niveles de plomo en sangre fueron medidos por espectrometría de masa, mientras que el daño del ADN fue determinado en linfocitos de sangre periférica con el empleo de un ensayo de electroforesis alcalina (ensayo del cometa). Resultados: no se mostró diferencia significativa en los niveles de plomo entre los grupos. El daño del ADN fue mayor en los pacientes autistas en relación con el grupo control, cuya diferencia fue significativa (p< 0,05), cuando comparamos los grupos teniendo en cuenta la severidad del retardo mental. Los pacientes con trastorno moderado/severo mostraron un daño del ADN significativamente superior a los que presentaron trastornos ligeros y al grupo control. Conclusiones: los resultados confirman la presencia de daño del ADN en pacientes con trastornos del espectro autista, lo cual sugiere que este pudiera ser un factor que se relaciona con la severidad del retardo mental en estos enfermos(AU)

Introduction:autistic spectrum disorders are considered to be a family of neurodevelopmental alterations characterized by difficulty to communicate and interact socially, as well as stereotyped, repetitive behavior. Though several hypotheses involve genetic and environmental factors in the etiopathogeny of this condition, their actual participation is still unknown. The present study explores the relationship between serum lead levels, DNA damage and the severity of autism. Methods: a study was conducted with 15 children 4-11 years old diagnosed with autistic spectrum disorders and a control group from the same age range. The intelligence quotient was measured by the Terman-Merrill test, and children were classified into two degrees of mental retardation (mild and moderate/severe). Blood lead levels were measured by mass spectrometry, whereas DNA damage was determined in peripheral blood lymphocytes using the alkaline electrophoresis assay (the comet assay). Results: this study did not show any significant difference in lead levels between the groups. DNA damage was greater in autistic patients than in the control group, and the difference was significant (p<0.05) when mental retardation severity was considered. Patients with a moderate/severe disorder showed significantly greater DNA damage than those with mild disorders and the control group. Conclusions: results confirm the presence of DNA damage in patients with autistic spectrum disorders, suggesting that this factor could be related to mental retardation severity(AU)

Niveles de plomo y daño en el ADN en niños con trastornos del espectro autista / Lead levels and DNA damage in children with autistic spectrum disorders

Introducción: los trastornos del espectro autista se consideran una familia de alteraciones del neurodesarrollo, caracterizada por dificultades en la comunicación y la interacción social, así como la existencia de un comportamiento estereotipado y repetitivo. Aunque existen varias hipótesis que involucran a factores genéticos y ambientales en su etiopatogenia, la verdadera contribución de estos aún se desconoce. En este estudio se explora la relación entre los niveles séricos de plomo, el daño del ADN y la severidad del autismo. Métodos: se estudiaron 15 niños con el diagnóstico de trastornos del espectro autista entre 4 y 11 años de edad y un grupo control del mismo rango de edad. El coeficiente de inteligencia fue evaluado mediante la prueba de Terman-Merrill y los niños fueron clasificados en dos grados de retardo mental (ligero y moderado/severo). Los niveles de plomo en sangre fueron medidos por espectrometría de masa, mientras que el daño del ADN fue determinado en linfocitos de sangre periférica con el empleo de un ensayo de electroforesis alcalina (ensayo del cometa). Resultados: no se mostró diferencia significativa en los niveles de plomo entre los grupos. El daño del ADN fue mayor en los pacientes autistas en relación con el grupo control, cuya diferencia fue significativa (p< 0,05), cuando comparamos los grupos teniendo en cuenta la severidad del retardo mental. Los pacientes con trastorno moderado/severo mostraron un daño del ADN significativamente superior a los que presentaron trastornos ligeros y al grupo control. Conclusiones: los resultados confirman la presencia de daño del ADN en pacientes con trastornos del espectro autista, lo cual sugiere que este pudiera ser un factor que se relaciona con la severidad del retardo mental en estos enfermos

Introduction:autistic spectrum disorders are considered to be a family of neurodevelopmental alterations characterized by difficulty to communicate and interact socially, as well as stereotyped, repetitive behavior. Though several hypotheses involve genetic and environmental factors in the etiopathogeny of this condition, their actual participation is still unknown. The present study explores the relationship between serum lead levels, DNA damage and the severity of autism. Methods: a study was conducted with 15 children 4-11 years old diagnosed with autistic spectrum disorders and a control group from the same age range. The intelligence quotient was measured by the Terman-Merrill test, and children were classified into two degrees of mental retardation (mild and moderate/severe). Blood lead levels were measured by mass spectrometry, whereas DNA damage was determined in peripheral blood lymphocytes using the alkaline electrophoresis assay (the comet assay). Results: this study did not show any significant difference in lead levels between the groups. DNA damage was greater in autistic patients than in the control group, and the difference was significant (p<0.05) when mental retardation severity was considered. Patients with a moderate/severe disorder showed significantly greater DNA damage than those with mild disorders and the control group. Conclusions: results confirm the presence of DNA damage in patients with autistic spectrum disorders, suggesting that this factor could be related to mental retardation severity

Enfermedad de hnntington: modelos experimentales y perspectivas terapéuticas / Huntington'disease: Experimentals Models and Therapeutic Perspectives

La enfermedad de Huntington (EH) es un trastorno degenerativo de Weiss de origen hereditario. Hasta el momento no existe un tratamiento efectivo para la enfermedad que inexorablemente después de transcurridos 15 a 20 años, evoluciona hacia incapacidad total o muerte. En este trabajo se revisan las características clínicas y morfológicas de la EH y los modelos experimentales más utilizados para su estudio tomando como fuente, artículos indexados en la base de datos Medline publicados en los últimos 20 años. Se valoran las ventajas y desventajas de estos modelos y su perspectiva para el desarrollo de ensayos clínicos. El consenso de lo reportado plantea que de los modelos tóxicos, los inducidos por neurotoxinas tales como ácido quinolínico parecen ser los más adecuados para reproducir las características neuropatológicas, y por otro lado los modelos genéticos contribuyen con más evidencias al conocimiento del origen etiológico de la enfermedad. Numerosos tratamientos han sido aplicados en el manejo de las manifestaciones clínicas que aparecen en EH, sin poder detener o disminuir las afectaciones que derivan de la pérdida neuronal. La sintomatología clínica ha sido posible reproducirla, al menos en parte, en animales de experimentación lo que ha permitido realizar ensayos terapéuticos. Desde el punto de vista de tratamiento, lo que más promisorio parece ser, la terapia celular con células provenientes de diferentes fuentes y dentro de ellas las no neurales, que implican menor censura ética y mayor factibilidad de obtención para la aplicación en los enfermos. Por otro lado el desarrollo de la tecnología del ARN de interferencia, emerge como una herramienta terapéutica potencial para el tratamiento de EH, así como para responder interrogantes básicas relacionadas con el desarrollo de la enfermedad.

Huntington'disease (HD) is a degenerative dysfunction of hereditary origin. Up to date there is not, an effective treatment to the disease which having lapsed 15 or 20 years advances inexorably, in a slow form, toward the total inability or death. This paper reviews the clinical and morphological characteristics of Huntington's disease as well as the experimental models more commonly used t study this disease, having as source the articles indexed in Medline data base, published in the last 20 years. Advantages and disadvantages of all experimental models to reproduce the disease as well as the perspectives to therapeutic assay have been also considered. The consent of outline reported about the toxic models, those induced by neurotoxins such as quinolinic acid, appears to be the most appropiate to reproduce the neuropathologic characteristic of the disease, an genetic models contributing with more evidence to the knowledge of the disease ethiology. Numerous treatments ameliorate clinical manifestations, but none of them has been able to stop or diminish the affectations derived from neuronal loss. At present time it is possible to reproduce, at least partially, the characteristics of the disease in experimentation animals that allow therapy evaluation in HD. From the treatment view point, the more promissory seems to be transplantation of no neuronal cells, taking into account ethical issues and factibility. On the other hand the new technology of interference RNA, emerges as a potential therapeutic tool for treatment in HD, and to respond basic questions on the development of the disease.

Análisis básico del LCR: relación al diagnóstico patológico en las demencias / Basic analysis of the LCR: relationship to the demetia pathological diagnosis

La respuesta inmune humoral en el sistema nervioso central (SNC) muestra patrones de respuesta de síntesis intratecal de inmunoglobulina dependiente de la causa, la fisiopatología y localización de la enfermedad y no del estado agudo o crónico del proceso patológico de que se trate, como ocurre en la periferia. Estos elementos resultan de utilidad para caracterizar el patrón de respuesta de anticuerpos en el SNC referido a la neuropatología de las enfermedades neurológicas. Nuestro trabajo reporta los patrones de la respuesta para las tres clases de inmunoglobulinas en 15 pacientes con el diagnóstico de demencia tipo Alzheimer comparado con otros tipos de demenia: demencia vascular y demencia secundaria a neurosífilis. Para el análisis, se realizó la estimación cuantitativa de las proteínas, albúmina, IgG, IgM, e IgA en suero y LCR por método inmunocitoquímico nefelométrico estándar. La razón albúmina (RA) LCR/suero y la síntesis intratecal de IgG fueron calculadas por el ploteo automatizado de las razones de la concentración de las proteínas en ambos fluídos en el diagrama de reiber (Reibergrama).(AU)